Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Transplantation

The role of RAAS blockade in kidney transplantation

Nature Reviews Nephrology volume 12, pages 129–131 (2016)Cite this article

Subjects

Blockade of the renin–angiotensin–aldosterone system (RAAS) slows the progression of many forms of kidney disease, but whether this therapy is beneficial in kidney transplant recipients is unclear. A new randomized controlled trial suggests that RAAS blockade is not beneficial in the transplant setting, but the underpowered nature of this study limits its conclusions.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gondos, A., Dohler, B., Brenner, H. & Opelz, G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation 95, 267–274 (2013).

    Article  Google Scholar 

  2. Knoll, G. A. et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. http://dx.doi.org/10.1016/S2213-8587(15)00368-X (2015).

  3. Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456–1462 (1993).

    Article  CAS  Google Scholar 

  4. Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).

    Article  CAS  Google Scholar 

  5. Heinze, G. et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J. Am. Soc. Nephrol. 17, 889–899 (2006).

    Article  CAS  Google Scholar 

  6. Ibrahim, H. N. et al. Angiotensin II blockade in kidney transplant recipients. J. Am. Soc. Nephrol. 24, 320–327 (2013).

    Article  CAS  Google Scholar 

  7. Philipp, T. et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol. Dial. Transplant. 25, 967–976 (2010).

    Article  CAS  Google Scholar 

  8. Mariat, C. Early use of renin−angiotensin−aldosterone system inhibitors after renal transplantation. Nat. Clin. Pract. Nephrol. 4, 306–307 (2008).

    Article  CAS  Google Scholar 

  9. Rossi, A. P. & Vella, J. P. Hypertension, living kidney donors, and transplantation: where are we today? Adv. Chronic Kidney Dis. 22, 154–164 (2015).

    Article  Google Scholar 

  10. Prokai, A. et al. Calcineurin-inhibition results in upregulation of local renin and subsequent vascular endothelial growth factor production in renal collecting ducts. Transplantation http://dx.doi.org/10.1097/TP.0000000000000961 (2015).

Download references

Acknowledgements

R.D.T. is supported by the National Center for Advancing Translational Sciences of the NIH under award number UL1TR001105. The content is solely the responsibility of the author and does not necessarily represent the official views of the NIH.

Author information

Authors and Affiliations

  1. Division of Nephrology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, 10526 Ravenscroft Drive, Dallas, 75390, Texas, USA

    Robert D. Toto

Authors
  1. Robert D. Toto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert D. Toto.

Ethics declarations

Competing interests

R.D.T has received honoraria for consulting and advisory board activities from Amgen, Boehringer–Ingelheim, Celgene, Relypsa, and ZS Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toto, R. The role of RAAS blockade in kidney transplantation. Nat Rev Nephrol 12, 129–131 (2016). https://doi.org/10.1038/nrneph.2015.201

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2015.201

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing